MarketCap
Facebook
X
Telegram
Evolent Health Revenue | EVH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Evolent Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 469 M | 647 M | 556 M | 382 M | 248 M | 925 M | 846 M | 627 M | 435 M | 254 M | 96.9 M | - | 25.7 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 925 M | 25.7 M | 459 M |
Quarterly Revenue Evolent Health
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 653 M | 496 M | 480 M | 444 M | 484 M | 621 M | 647 M | 640 M | 511 M | 469 M | 428 M | - | 353 M | - | 297 M | 248 M | 222 M | 222 M | 215 M | 247 M | 240 M | 217 M | 221 M | 237 M | 220 M | 192 M | 198 M | 193 M | 150 M | 144 M | 140 M | 114 M | 108 M | 107 M | 106 M | - | -448 K | -14 K | - | - | - | -16.8 M | -11.3 M | - | -3.17 M | -5.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 653 M | -16.8 M | 262 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GoodRx Holdings
GDRX
|
797 M | $ 3.53 | 4.13 % | $ 1.26 B |  USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.77 | 3.82 % | $ 124 M | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 95.89 | 0.25 % | $ 8.26 B | USA |
 |
HealthStream
HSTM
|
304 M | $ 29.6 | 1.68 % | $ 889 M | USA |
 |
Omnicell
OMCL
|
1.18 B | $ 33.57 | 2.38 % | $ 1.54 B | USA |
 |
OptimizeRx Corporation
OPRX
|
109 M | $ 7.72 | 5.9 % | $ 143 M | USA |
 |
Progyny
PGNY
|
318 M | $ 27.73 | 1.39 % | $ 2.36 B | USA |
 |
Phreesia
PHR
|
481 M | $ 10.34 | 0.29 % | $ 618 M | USA |
 |
Schrödinger
SDGR
|
256 M | $ 20.55 | 8.02 % | $ 1.51 B | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 6.54 | 6.09 % | $ 1.15 B | USA |
 |
10x Genomics
TXG
|
643 M | $ 69.83 | 1.81 % | $ 8.71 B | USA |
 |
Veeva Systems
VEEV
|
3.2 B | $ 265.27 | 1.09 % | $ 43.4 B | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
594 M | - | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
1Life Healthcare
ONEM
|
1.05 B | - | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
3.48 B | - | - | $ 9.03 B | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 13.92 | 6.58 % | $ 223 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
Zhongchao
ZCMD
|
11.4 M | $ 0.75 | 4.0 % | $ 2.56 M |  China |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
So-Young International
SY
|
1.52 B | $ 2.67 | 0.74 % | $ 208 M | China |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
NextGen Healthcare
NXGN
|
653 M | - | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
414 M | - | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
347 M | - | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
185 M | - | - | $ 161 M | USA |
 |
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
2.88 M | - | - | $ 7.71 M | USA |